Designing a modular, open and expandable Bluetooth-platform

Lähitulevaisuudessa langattomien järjestelmien kaupalliset mahdollisuudet tulevat olemaan valtavia. Tutkiaksemme tulevia tarpeita, tässä diplomityössä esitellään kuinka voidaan suunnitella ja toteuttaa avoin langaton asiakas-palvelin järjestelmä. Järjestelmänä päätettiin käyttää Bluetooth:ia. Tutkituista langattomista standardeista Bluetooth sopii parhaiten akkukäyttöiselle laitteelle, jonka tulee olla monipuolinen. Lisäksi Bluetooth:iin on liitetty suuria kaupallisia odotuksia ja yksi työn tavoitteista olikin tutkia, ovatko nämä odotukset realistisia. Bluetooth:iin havaittiin liittyvän paljon ylimainontaa ja, sen todettiin olevan monimutkainen. Sillä on kuitenkin paljon ominaisuuksia ja erilaisten käyttöprofiilien avulla sitä voidaan käyttää monenlaisiin tehtäviin. Suunniteltu järjestelmä ajaa socket-palvelinta Bluetooth-yhteyden päällä. Tietyntyyppiseen liikenteeseen erikoistuneet socket:t tarjoavat vaaditun laajennattavuuden. Palvelin toteutetiin Linux-säikeenä ja se hallitsee Bluetooth protokollapinoa sekä sovelluksia, joita suoritetaan palvelimella. Näiden sovelluksien palvelut ovat muiden käytössä Bluetooth:n kautta.

Respecting the deal: Economically sustainable management of open innovation among co-opeting companies

Platforms like eBay allow product seekers and providers to meet and exchange goods. On eBay, consumers can return a product if it does not correspond to expectations; eBay is the third-party firm in charge of assuring that the agreement among seekers and providers will be respected. Who provides the same service for what concerns open innovation, where specifications might not fully defined? This paper describes the business model of an organizational structure to support the elicitation and respect of agreements among agents, who have conflicting interests but that gain from cooperating together. Extending previous studies, our business model takes into account the economic dimensions concerning the needs of knowledge share and mutual control to allow a third-party to sustainably reinforce trust among untrusted partners and to lower their overall relational risk.

Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.

BACKGROUND: Survival outcomes for patients with glioblastoma remain poor, particularly for patients with unmethylated O(6)-methylguanine-DNA methyltransferase (MGMT) gene promoter. This phase II, randomized, open-label, multicenter trial investigated the efficacy and safety of 2 dose regimens of the selective integrin inhibitor cilengitide combined with standard chemoradiotherapy in patients with newly diagnosed glioblastoma and an unmethylated MGMT promoter. METHODS: Overall, 265 patients were randomized (1:1:1) to standard cilengitide (2000 mg 2×/wk; n = 88), intensive cilengitide (2000 mg 5×/wk during wk 1-6, thereafter 2×/wk; n = 88), or a control arm (chemoradiotherapy alone; n = 89). Cilengitide was administered intravenously in combination with daily temozolomide (TMZ) and concomitant radiotherapy (RT; wk 1-6), followed by TMZ maintenance therapy (TMZ/RT→TMZ). The primary endpoint was overall survival; secondary endpoints included progression-free survival, pharmacokinetics, and safety and tolerability. RESULTS: Median overall survival was 16.3 months in the standard cilengitide arm (hazard ratio [HR], 0.686; 95% CI: 0.484, 0.972; P = .032) and 14.5 months in the intensive cilengitide arm (HR, 0.858; 95% CI: 0.612, 1.204; P = .3771) versus 13.4 months in the control arm. Median progression-free survival assessed per independent review committee was 5.6 months (HR, 0.822; 95% CI: 0.595, 1.134) and 5.9 months (HR, 0.794; 95% CI: 0.575, 1.096) in the standard and intensive cilengitide arms, respectively, versus 4.1 months in the control arm. Cilengitide was well tolerated. CONCLUSIONS: Standard and intensive cilengitide dose regimens were well tolerated in combination with TMZ/RT→TMZ. Inconsistent overall survival and progression-free survival outcomes and a limited sample size did not allow firm conclusions regarding clinical efficacy in this exploratory phase II study.

Vakioidut optiot sähkökaupassa

Pohjoismaiset sähkömarkkinat ovat muuttuneet viime vuosina huomattavasti. Sähkömarkkinalakiuudistuksessa poistettiin muodollisesti kilpailun esteet, mutta uusien toimintamuotojen omaksuminen on Suomessa vasta alussa. Sähkömarkkinaosapuolet altistuvat riskriskeille, joita toimialalla ei ole aikaisemmin esiintynyt. Suurimpana riskitekijänä voidaan pitää epävarmuutta tulevasta sähkön hintatasosta, joka voi vaikuttaa merkittävästi yrityksen liiketoiminnan tulokseen. Tässä diplomityössä tarkastellaan, miten hinnanvaihtelua vastaan pystytään suojautumaan sähköjohdannaisten avulla. Kaupankäynti johdannaissopimuksilla edellyttää markkinoiden aktiivista seuraamista ja organisoitua sähkökaupan riskienhallintaa. Riskienhallinnan tehtävänä ei ole riskien eliminoiminen, vaan niiden sopeuttaminen yrityksen tuotto-odotuksien ja riskiensietokyvyn mukaisiksi. Ennen sähkömarkkinoiden avautumista suojauduttiin sähkön hintariskeiltä pitkillä toimitussopimuksilla. Uudessa markkinatilanteessa suojaus voidaan toteuttaa joustavasti ja kohtuullisin kustannuksin käyttämällä johdannaissopimuksia, joilla voidaan poistaa tulevaisuuteen kohdistuvaa epävarmuutta sähkönhinnasta. Pohjoismaisessa sähköpörssissä, Nord Pool ASA:ssa, noteerattavat johdannaiset ovat vakioituja. Lokakuun lopussa 1999 kaupankäynnin kohteeksi otetaan termiinien lisäksi myös vakioidut sähköoptiot. Option ostajalle avautuu mahdollisuus hintasuojaukseen instrumenteilla, joita käyttäen suojaustaso voidaan määrittää etukäteen. Vakioitujen sähköoptioiden mukaan ottaminen sähköpörssin tuotevalikoimaan monipuolistaa huomattavasti ostajien ja myyjien suojautumismahdollisuuksia. Suojaustasoa on tarpeen vaatiessa mahdollista muuttaa vastamaan uutta markkinatilannetta. Työn loppuosassa on tutkittu mahdollisia kaupankäyntistrategioita ja hinnoittelumalleja sähköoptioille. Koska tutkimus on tehty ennen pörssissä tapahtuvan optiokaupan alkamista, useisiin tässä työssä avoimiksi jääneisiin kysymyksiin tullaan saaman vastauksia käytännön kokemuksista.

Klammt's elastic open activator: Ricketts' cephalometrics results

The purpose of this study is to investigate the orthodontic and orthopaedic real effects of the Klammt's Elastic Open Activator (EOA) in 25 Class II Division 1 patients in growing period. We wanted to determine statistically the cephalometrics changes produced in the patients, comparing the lateral cranium teleradiographies we took for the diagnosis with the ones we took at the end of treatment. At the end of this study we confirm that by using the EOA we obtained the desired effects, especially reducing the molar relation 2.53 mm and the overjet 2.56 mm. The EOA corrected the inclination and protrusion of incisors, although we cannot avoid the use of fixed appliances to round off. The reduction of 2.48 mm of facial convexity stands out as the most important skeletal effect; the facial depth angle increases 0.8 degree, and the maxillary depth decreases 1.16 degrees. The length of the mandibular corpus also increases 6.7 mm, although this change is mainly due to the growth of the patient. The changes in the aesthetic profile do not stand out

Molecular Analysis of NOTCH2 in Patients with Primary Open-Angle Glaucoma.

BACKGROUND AND PURPOSE: Transgenic mice overexpressing Notch2 in the uvea exhibit a hyperplastic ciliary body leading to increased IOP and glaucoma. The aim of this study was to investigate the possible presence of NOTCH2 variants in patients with primary open-angle glaucoma (POAG). METHODS: We screened DNA samples from 130 patients with POAG for NOTCH2 variants by denaturing high-performance liquid chromatography after PCR amplification and validated our data by direct Sanger sequencing. RESULTS: No mutations were observed in the coding regions of NOTCH2 or in the splice sites. 19 known SNPs (single nucleotide polymorphisms) were detected. An SNP located in intron 24, c.[4005+45A>G], was seen in 28.5% of the patients (37/130 patients). As this SNP is reported to have a minor allele frequency of 7% in the 1000 genomes database, it could be associated with POAG. However, we evaluated its frequency in an ethnic-matched control group of 96 subjects unaffected by POAG and observed a frequency of 29%, indicating that it was not related to POAG. CONCLUSION: NOTCH2 seemed to be a good candidate for POAG as it is expressed in the anterior segment in the human eye. However, mutational analysis did not show any causative mutation. This study also shows that proper ethnic-matched control groups are essential in association studies and that values given in databases are sometimes misleading.

Optimal Exchange Rate Policy in a Growing Semi-Open Economy

This paper considers an alternative perspective to China's exchange rate policy. It studies a semi-open economy where the private sector has no access to international capital markets but the central bank has full access. Moreover, it assumes limited financial development generating a large demand for saving instruments by the private sector. The paper analyzes the optimal exchange rate policy by modeling the central bank as a Ramsey planner. Its main result is that in a growth acceleration episode it is optimal to have an initial real depreciation of the currency combined with an accumulation of reserves, which is consistent with the Chinese experience. This depreciation is followed by an appreciation in the long run. The paper also shows that the optimal exchange rate path is close to the one that would result in an economy with full capital mobility and no central bank intervention.

Secondhand tobacco smoke exposure in open and semi-open settings: a systematic review

Background: Some countries have recently extended smoke-free policies to particular outdoor settings; however, there is controversy regarding whether this is scientifically and ethically justifiable. Objectives: The objective of the present study was to review research on secondhand smoke (SHS) exposure in outdoor settings. Data sources: We conducted different searches in PubMed for the period prior to September 2012. We checked the references of the identified papers, and conducted a similar search in Google Scholar. Study selection: Our search terms included combinations of"secondhand smoke,""environmental tobacco smoke,""passive smoking" OR"tobacco smoke pollution" AND"outdoors" AND"PM" (particulate matter),"PM2.5" (PM with diameter ≤ 2.5 µm),"respirable suspended particles,""particulate matter,""nicotine,""CO" (carbon monoxide),"cotinine,""marker,""biomarker" OR"airborne marker." In total, 18 articles and reports met the inclusion criteria. Results: Almost all studies used PM2.5 concentration as an SHS marker. Mean PM2.5 concentrations reported for outdoor smoking areas when smokers were present ranged from 8.32 to 124 µg/m3 at hospitality venues, and 4.60 to 17.80 µg/m3 at other locations. Mean PM2.5 concentrations in smoke-free indoor settings near outdoor smoking areas ranged from 4 to 120.51 µg/m3. SHS levels increased when smokers were present, and outdoor and indoor SHS levels were related. Most studies reported a positive association between SHS measures and smoker density, enclosure of outdoor locations, wind conditions, and proximity to smokers. Conclusions: The available evidence indicates high SHS levels at some outdoor smoking areas and at adjacent smoke-free indoor areas. Further research and standardization of methodology is needed to determine whether smoke-free legislation should be extended to outdoor settings.

Pelin kehitys win32-alustalla käyttäen Open Source -työkaluja

Peliteollisuus on nykyään erittäin suuri ohjelmistokehityksen ala, joten on ajankohtaista tutustua ilmaisten työkalujen ja kirjastojen tarjoamiin mahdollisuuksiin. Visuaalisen viihteen tuottamiseen tarvitaan yleensä C++-ohjelmointitaidon lisäksi mallinnustaitoa ja kuvankäsittelytaitoa. Tämän lisäksi äänten tuottaminen on erittäin suuri osa toimivan kokonaisuuden saavuttamiseksi. Tässä työssä käsitellään kaikki osa-alueet ja tutkitaan Open Source -työkalujen soveltuvuutta pelin kehitykseen win32-alustalla. Lopputuloksena syntyy täysin pelattava, tosin yksinkertainen peli CrazyBunny. Työn alussa esitellään kaikki käytettävät työkalut jotka kuuluvat tarvittavaan kehitysympäristöön. Tähän esittelyyn kuuluvat myös olennaisena osana työkalujen asennuksen läpikäynti sekä käyttöönotto. Työn perustana on käytetty OGRE-ohjelmistokehystä, joka ei ole varsinainen pelimoottori. Puuttuvia ominaisuuksia on lisätty käyttämällä CEGUI-kirjastoa käyttöliittymien tekoon sekä FMOD-kirjastoa äänijärjestelmän toteutukseen. Muita käytet-tyjä työkaluja ovat Code::Blocks-kehitysympäristö, Blender-mallinnusohjelma ja Audacity-äänieditori. Pelisovelluksen toteutuksen pohjana on käytetty State-sunnittelumalliin perustuvaa järjes-telmää pelitiloja hallintaan. Tässä mallissa pelin päävalikko, pelitila ja pelin loppu on ero-tettu omiksi tilaluokikseen, jolloin sovelluksesta saadaan helpommin hallittava. Päävali-kossa tärkein osa on itse valikoiden toteutus CEGUI-kirjaston avulla. Pelitilan toteutukses-sa tutustutaan OGRE:n visuaalisiin ominaisuuksiin kuten ympäristöön, valoihin, varjoihin, kuva-alustoihin ja visuaalisiin tehosteisiin. Tämän lisäksi peliin on toteutettu äänet suosi-tulla FMOD-kirjastolla, jota useat isot alan yritykset käyttävät kaupallisissa tuotteissaan.

A thematic analysis of delusion with religious content in schizophrenia: open, closed, and mixed dynamics

The aim of the present study was to elicit how patients with delusions with religious contents conceptualized or experienced their spirituality and religiousness. Sixty-two patients with present or past religious delusions went through semistructured interviews, which were analyzed using the three coding steps described in the grounded theory. Three major themes were found in religious delusions: ''spiritual identity,'' ''meaning of illness,'' and ''spiritual figures.'' One higher-order concept was found: ''structure of beliefs.'' We identified dynamics that put these personal beliefs into a constant reconstruction through interaction with the world and others (i.e., open dynamics) and conversely structural dynamics that created a complete rupture with the surrounding world and others (i.e., closed structural dynamics); those dynamics may coexist. These analyses may help to identify psychological functions of delusions with religious content and, therefore, to better conceptualize interventions when dealing with it in psychotherapy.

STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer.

BACKGROUND: The management of unresectable metastatic colorectal cancer (mCRC) is a comprehensive treatment strategy involving several lines of therapy, maintenance, salvage surgery, and treatment-free intervals. Besides chemotherapy (fluoropyrimidine, oxaliplatin, irinotecan), molecular-targeted agents such as anti-angiogenic agents (bevacizumab, aflibercept, regorafenib) and anti-epidermal growth factor receptor agents (cetuximab, panitumumab) have become available. Ultimately, given the increasing cost of new active compounds, new strategy trials are needed to define the optimal use and the best sequencing of these agents. Such new clinical trials require alternative endpoints that can capture the effect of several treatment lines and be measured earlier than overall survival to help shorten the duration and reduce the size and cost of trials. METHODS/DESIGN: STRATEGIC-1 is an international, open-label, randomized, multicenter phase III trial designed to determine an optimally personalized treatment sequence of the available treatment modalities in patients with unresectable RAS wild-type mCRC. Two standard treatment strategies are compared: first-line FOLFIRI-cetuximab, followed by oxaliplatin-based second-line chemotherapy with bevacizumab (Arm A) vs. first-line OPTIMOX-bevacizumab, followed by irinotecan-based second-line chemotherapy with bevacizumab, and by an anti-epidermal growth factor receptor monoclonal antibody with or without irinotecan as third-line treatment (Arm B). The primary endpoint is duration of disease control. A total of 500 patients will be randomized in a 1:1 ratio to one of the two treatment strategies. DISCUSSION: The STRATEGIC-1 trial is designed to give global information on the therapeutic sequences in patients with unresectable RAS wild-type mCRC that in turn is likely to have a significant impact on the management of this patient population. The trial is open for inclusion since August 2013. TRIAL REGISTRATION: STRATEGIC-1 is registered at Clinicaltrials.gov: NCT01910610, 23 July, 2013. STRATEGIC-1 is registered at EudraCT-No.: 2013-001928-19, 25 April, 2013.